Purpose: Patients with uveal melanoma (UM) undergo lifelong follow-up as metastases can occur more than 20 years after diagnosis. Little is known about the quality of life (QoL) of UM survivors over such an extended period. To investigate their QoL, we used various estimating factors. Methods: A cohort of patients diagnosed and treated for UM with regularly scheduled follow-up visits was asked to fill in a European Organization for Research and Treatment of Cancer (EORTC) questionnaire comprised of the EORTC QLQ-C30 and EORTC QLQ-OPT30 modules. An additional open question examined other changes in the patients' lifestyle since diagnosis. Independent demographic and medical data were collected from patient records. Results: Two hundred and thirty-two of 294 patients agreed to complete the questionnaire. General QoL correlated highly with the eye-related QoL. Statistically significant higher QoL was associated with tumours not involving the ciliary body, and with better best-corrected visual acuity (BCVA). A subgroup of 39% of the patients reported severe disability affecting eye-related tasks. Thirty-three per cent were highly concerned about various aspects of their future health. Patients who underwent enucleation reported lower eye-related QoL and described problems related to body image in response to the open question. Conclusion: General QoL of UM patients is only slightly affected by their malignancy. However, body image and psychosocial adjustment are major issues involved in evaluating QoL. Continuous long-term psychosocial treatment is needed from the time of diagnosis in a subgroup of patients suffering from eye-related disabilities.
Introduction
Improvement in treatment methods and the resulting rise in cancer survival rates turn cancer from an acute to a chronic illness for many patients. Facing quality of life (QoL) and psychosocial challenges that a patient encounters (Avis et al. 2005 ) on returning to the community after cancer treatment is an increasingly important issue which needs to be addressed. The impact of the illness on the daily life of uveal melanoma (UM) patients and their family members is an important research theme which has hardly been examined in long-term patients with UM who are a rare population of cancer patients. In addition to the threat to their lives and the fear of recurrence of the disease, they suffer from the possibility of vision impairment and cosmetic damage to their eyes. Moreover, they undergo lifelong follow-up as metastases can occur more than 20 years after diagnosis (Shields et al. 1985; Gunduz et al. 1998) . Little is known about the QoL of UM cancer survivors throughout such a long follow-up period. The most known QoL study regarding this population was the Collaborative Ocular Melanoma Study-quality of life study (COMS-QOLS) which assessed the QoL of patients with medium-sized tumours and compared two treatment arms (brachytherapy and enucleation) over a period of up to 5 years (Claudia & Michele 1999; Melia et al. 2003 Melia et al. , 2006 .
The population of cancer survivors has been investigated both quantitatively and qualitatively, mostly regarding breast cancer (Helgeson & Tomich 2005) , prostate cancer (Thornton & Perez 2006 ) and bone marrow transplantation survivors (Molassiotis 1997 ). The QoL is one of the most investigated issues in these cancer survivors and demonstrates that most long-term survivors report retrospectively that cancer either had a positive influence or hardly any long-term impact on their lives. However, QoL is reduced as a result of pain, physical deformities or social isolation (Foley et al. 2006) . Quantitative findings indicate that cancer-related health worries are a significant predictor of depression and anxiety (Deimling et al. 2006 ). The objective progression or regression of disease state is not as important to cancer survivors' wellbeing as is the patient's attributes (Gotay et al. 2004 ). The QoL of cancer survivors was found to be correlated with income level: survivors with high income enjoy better QoL than what is expected based on the mere correlation between health and earnings (Short & Mallonee 2006) . Age at diagnosis, marital status, employment and education was found to be among the most significant variables in the perception of personal growth of breast cancer survivors (Bellizzi & Blank 2006) . Long-term survivors (5 or more years post-diagnosis) report less worry and better functioning than recent survivors (Rothrock 2004) .
This study examined all UM cancer survivors who have been followed up for up to 20 years. Our research evaluated the QoL and additional variables at various time-points after treatment in the largest cohort of UM patients to be studied to date.
Patients and Methods
A cohort of 294 patients who were treated for UM at the Ocular Oncology Clinic of the Department of Ophthalmology of the Hadassah-Hebrew University Medical Center was asked to fill in a questionnaire comprised of two QoL questionnaire modules. These questionnaires were developed and validated for the European Organization for Research and Treatment of Cancer (EORTC): the general EORTC QLQ-C30 and the Ophthalmic Oncology EORTC QLQ-OPT30 (Brandberg et al. 2004; Chmielowska et al. 2013) . The modules were translated into Hebrew. The questionnaire was completed during a regular clinic visit. Answers ranged from 1 (completely unaffected) to 4 (severely affected). Based on the two QoL questionnaires, two scores were computed for every participant: general QoL and eyerelated QoL. Additionally, questionnaire items (questions) were grouped into the following parameters: (1) restricted activity (q1-q7), (2) physical symptoms (q8-12, q18-19), (3) gastrointestinal problems (q13-q17), (4) mental symptoms (q20-q25), (5) worries about the future (q38-q42), (6) treatment interfering with life (q26-q28, q48), (7) cosmetics (satisfaction with cosmetic outcome of the surgery) (q45-q46), (8) problems with the treated eye (q31-q37, q54-q60) and (9) problems with sight (q43, q44, q47, q50-q53 ). An open question requested a description of other changes in the patient's life since diagnosis. Independent demographic and medical variables were collected from medical records, including age at time of diagnosis, affected eye, initial tumour parameters [intraocular location, largest basal diameter (LBD) and tumour height], primary treatment type and additional treatments (if applicable), best-corrected visual acuity (BCVA, converted to LogMAR) in the treated eye and the unaffected eye at the time of filling in the questionnaire, metastatic status at the time of filling in the questionnaire and other known malignancies. Tumour size was classified by the AJCC 7th edition TNM classification (Kujala et al. 2013 In the study group, six patients had a tumour confined to the iris; six had irido-ciliary tumours; two had irido-cilio-choroidal tumours; seven were confined to the ciliary body; 20 had cilio-choroidal tumours of which one extended posteriorly to the equator; and in 20, the tumour was limited to the anterior choroid; in 74, the tumour was equatorial; and in 98, the tumour was confined to the posterior choroid. The T-size category classification for these tumours is presented in Table 1 .
The mean score of each tested item in the EORTC-QLQ-OPT-30 questionnaire is given in Table 2 , as well as the percentage of patients with moderate to severe complaints. The items in the combined questionnaire (C30 and OPT30 modules) were grouped into nine parameters [restricted activity, physical symptoms, gastrointestinal (GI) problems, mental symptoms, worries about the future, treatment interferes with life, cosmetics, problems with the treated eye and problems with sight] which were summarized into a general QoL score and an eye-related QoL score. The mean scores for these calculated parameters along with the percentage of patients with moderate to severe scores are given in Table 3 . Correlations were computed for each pair of parameters. The highest correlation was found between problems with the treated eye and worries about the future; between GI and physical symptoms; and between problems with the treated eye and problems with limited sight (Table 4) . Table 1 . TNM (7) T-size category: The T-size category distribution of tumours according to the TNM 7 classification (Kujala et al. 2013 The QoL variables were tested for correlation with known clinical information about the patients. None of the tests resulted in more than a weak correlation (0 < r < 0.5) despite having statistical significance. None of the QoL variables correlated with laterality, enucleation, or the LBD of the tumour. The patients' age at diagnosis correlated with the restricted activity QoL score, with physical symptoms, with GI symptoms, with a lower sense of cosmetic problems and with increased sight-limiting problems (Table 5) . Tumour height correlated with cosmetics (r = 0.216, p = 0.001, Pearson's Chi-squared). Tumours located within the ciliary body (CB) correlated with a higher score (worse QoL) in the following QoL parameters: worries about the future, cosmetics, problems with the treated eye, and problems related to limited sight. No systemic illness correlated with QoL other than by its effect on the measured symptoms such as GI symptoms. In the study population, 12.2% had additional other tumours, some diagnosed before the UM and some after it, but all had already finished the treatment course for the other malignancy at the time of the questionnaire filling. Having other tumours did not affect the QoL parameters of our UM patients.
Regarding the summary parameters, the general QoL correlated highly with the eye-related QoL (r = 0.790, p < 0.0001, Pearson's Chi-squared). The general QoL score did not vary in a statistically significant manner for the different types of initial treatment (Fig. 1) . Even the cosmetics parameter did not differ among treatment types. However, patients who underwent an enucleation reported a lower eyerelated QoL (higher score) than patients who had brachytherapy (2.00 AE 0.75 versus 1.67 AE 0.56, p = 0.019, Fisher's exact test) (Fig. 1) . Moreover, many enucleated patients indicated that they are coping with substantial body image issues (e.g. avoiding having their picture taken because their eyes appear unequal in photographs, and avoiding social events because they are self-conscious regarding their appearance). In the open question on body image and psychosocial adjustment that had been added to the EORTC modules, it was surprising to discover that some of the patients who had low (good) scores in the quantitative QoL items reported different problems regarding body image and psychosocial adjustment issues.
We hypothesized that a more recent diagnosis and treatment would have a stronger effect on the patients' QoL and chose a 2-year cut-off. Sixty-one patients (26.2%) were treated up to 2 years before answering the questionnaire, and 172 (73.8%) were treated more than 2 years before answering the questionnaire. The only parameter which was found to somewhat correlate with the two-year cut-off was 'treatment interferes with life'. Analysing the parameter of 'treatment interferes with life' showed only a trend for a worse score, that is that the treatment affected patients' lives in the first 2 years more than from that time-point onwards (p = 0.073, Fisher's exact test). The other parameters did not correlate with the length of time from treatment, whether analysed continuously or divided into ≤ or >2 years since treatment.
Of the QoL variables, only 'cosmetics' was slightly affected by a need for recurrent treatment(s) (mean AE SD 1.66 AE 0.83 versus 1.32 AE 0.63 for retreated patients and one treatment only, respectively, r = 0.1814, p = 0.0 059). Retreated patients had a shorter time from treatment to filling in the questionnaire. Only nine of 34 (26%) retreatments were performed in the last 2 years before the study. Of only the retreated patients, there were more worries about the future if the last treatment was in the last 2 years (2.22 AE 0.92 versus 1.61 AE 0.70, r = 0.34, p = 0.047, Fisher's exact test), and no other parameters were affected.
Only 13 patients in this cohort of patients were diagnosed with metastatic disease at the time of completing the questionnaires, rendering the analysis of this factor invalid statistically. However, it was not surprising to find a significant trend towards a lower QoL in the general QoL variable (r = 0.13, p = 0.045, Fisher's exact test); more mental symptoms (r = 0.15, p = 0.021, Fisher's exact test); and more worries about the future (r = 0.13, p = 0.043, Fisher's exact test) among patients with metastases.
The BCVA of the tumour eye (median LogMAR 0.5 -equivalent to 20/ 63) correlated with problems with the treated eye parameter (r = 0.15, p = 0.042, Fisher's exact test) and with problems with sight (r = 0.28, p < 0.0001, Fisher's exact test), leading to a correlation with the eye-related QoL variable (r = 0.23, p = 0.001, Fisher's exact test). The BCVA of the nonaffected eye (median LogMAR 0.03 -equivalent to 20/20) correlated with restricted activity (r = 0.21, p = 0.001, Fisher's exact test), with physical symptoms (r = 0.14, p = 0.038, Fisher's exact test), with GI symptoms (r = 0.17, p = 0.010, Fisher's exact test) and with problems Table 4 . Parameter quality of life (QoL) score Spearman's R correlation: all the correlations are significant with p < 0.0001, except for both 'cosmetics' & 'restricted activity' (p = 0.0004) and 'cosmetics' & 'GI symptoms' (p = 0.0002). Light grey indicates a moderate correlation (0.5 < R < 0.75), and dark grey indicates a high correlation (0.75 < R < 1). with sight (r = 0.19, p = 0.007), with general QoL (r = 0.14, p = 0.039, Fisher's exact test) and with eye-related QoL (r = 0.15, p = 0.023, Fisher's exact test).
Discussion
To the best of our knowledge, this is the largest published QoL study dealing with UM patients, both regarding the number of participating patients and in the length of follow-up time from treatment. Damato and colleagues presented a QoL study in the 2011 European Vision and Eye Research (EVER) meeting, but results from that study were never published in full (Damato et al. 2011 ). The COMS QoL study (COMS-QOLS) excluded patients with visual acuity (VA) 20/200 or worse in the fellow eye or with an expected survival of fewer than 5 years due to concomitant health conditions (Melia et al. 2006 ). The response rate was 79% (209/265), just as in our study. Cruickshanks et al. (1999) tested whether the choice of treatment between enucleation and radiation therapy affected the QoL of 147 patients. Patients' QoL score was assessed after an average length of follow-up of 4.9 years for the group treated with radiation therapy and 6.3 years for the group treated with enucleation. The compliance of their patients to participate in the study was low (40%). In a study, validating the translation of the EORTC QLQ-C30 and QLQ-OPT questionnaires to Polish Chmielowska et al. (2013) had an excellent response rate (97%) and had only concluded that the test was valid. The National Eye Institute Visual Function Questionnaire (NEI VFQ-25) was developed for studies dealing with chronic eye diseases or low vision (Mangione et al. 2001) . We found that it was more appropriate for our UM patients to use a questionnaire that was created and validated especially for them. The Ophthalmic Oncology QoL questionnaire module was developed for the EORTC for cancer patients who in addition to the problem with their vision also have worries about a recurrence of the disease and fear of death (Brandberg et al. 2004 ). Furthermore, the treatment for the malignancy can also affect their lives.
Age-related macular degeneration (AMD) patients suffer from visual disturbances that can be severe. Patients with cancer usually do not have visual disturbances. Based on a comparison of the present research findings to findings regarding QoL of both other cancer patients and AMD patients (Taylor et al. 2016) , we can conclude that the general QoL of UM patients was slightly affected by their malignancy. This conclusion is strengthened by a study by Klingenstein et al. (2016) who compared the QoL of UM patients treated by either CyberKnife (irradiation) or enucleation to that of non-UM patients. They found that irradiation did not affect the QoL of UM patients, while enucleation only reduced the physical and emotional parameters. Similarly, long-term breast cancer survivors have a similar QoL as age-matched controls (Helgeson & Tomich 2005) . However, prostate cancer survivors have a decrease in QoL (Johansson et al. 2008) .
The general QoL of UM survivors in the present study was directly related to their eye-related QoL, and when the eye-related QoL decreased, so did the general QoL. Klingenstein et al. (2013) also found that a better BCVA correlated with a better QoL in UM patients. Moreover, in their later study, differences in QoL parameters between treatments (CyberKnife irradiation versus enucleation) disappeared when they only compared irradiated patients with a low final VA with enucleated patients (Klingenstein et al. 2016 ). In our study, the eye-related QoL was much better than that of patients suffering from chronic eye diseases such as AMD (Cruess et al. 2007 ). This is probably because our patients generally had excellent BCVA in the nonaffected eye, and the BCVA in the affected eye was good in more than half the patients. Additionally, we interpret the higher QoL in patients with tumours involving the iris to result from the fact that these tumours affect vision less than posterior tumours and result in fewer ocular discomfort. We realize that the group of patients with iris tumours is small, but given the known higher survival of these patients, we wanted to present this effect here knowing the readers will take it with a grain of salt.
A LBD increased height and an intraocular location in the ciliary body are known to be ominous prognostic factors. Location of the tumour within the CB correlated with a lower eyerelated QoL, due to dissatisfaction with cosmetics, problems in the treated eye and heightened worries about the future. Height was only correlated with cosmetics (due to the need to enucleate very high tumours), whereas LBD was not correlated with any QoL parameters. This finding raises the question of how UM patients perceive the provision of prognostic factors which we give routinely, although this issue was not assessed in our study. Patients with better eye-related QoL can go on with their everyday routine, not feeling the impact of the illness on their life and therefore being less worried regarding the future. However, severe symptoms in UM patients serve as a constant reminder of the illness, which leads to worries regarding future implications of cancer. Chabert et al. (2004) who ran a similar study to ours albeit over a short period of follow-up called for a longterm evaluation of QoL. Our findings for the initial 2 years of follow-up corroborate theirs. Our long-term follow-up answers their question and shows that the QoL improves with time, mostly in those patients with a good BCVA.
Analysis of the open question about body image and psychosocial adjustment that was added to the EORTC modules identified differences between the 'objective' numerical parameters and the 'subjective' difficulties experienced by the patients. These differences were most evident in the analysis of the effect of treatment choice on the QoL. Cruickshanks found no differences between radiation-and enucleationrelated QoL (Cruickshanks et al. 1999) . The data presented by Chabert and by Klingenstein tell a different story that matches our findings (Chabert et al. 2004; Klingenstein et al. 2016) . Our enucleated patients reported a lower eye-related QoL, in comparison with a high general QoL score in brachytherapy-treated patients. However, in the answers to the open question, many enucleated patients indicated that they deal with substantial body image issues. This finding could indicate that the questionnaire should be reappraised, possibly adding more specific questions regarding the effect of surgery on social activities and satisfaction with self-image.
The age at the time of diagnosis was correlated with some of the measured parameters that are related to general health such as restricted activity, physical symptoms, and GI problems. It may indicate that at least part of the reduction in the QoL in older patients is not related to the UM, but to their general health.
The small size of the group of metastatic patients within this cohort does not allow a proper statistical analysis of the impact of this factor on the QoL. However, the unmistakable trend of worsened QoL reported in this group should prompt close attention to these issues in this group in addition to their medical treatment (Siddiqi et al. 2009 ).
We chose not to exclude patients with additional malignancies as our aim was to study the general population of an ocular oncology referral clinic, in which some patients have additional other malignancies. Indeed, this subgroup was not different from patients with only UM. Information on the general health of the patients relied only on what was reported by the patients in response to question #29 rating their general health in the week before filling the questionnaire from 1 to 7 (with seven being excellent health).
Amaro and colleagues who studied depression and QoL of enucleated UM patients over the year from diagnosis and on found that by 1 year after the enucleation, the worries subsided with a more balanced QoL (Amaro et al. 2010 ). Damato and colleagues found that QoL improves after 6-18 months (personal communication), and so did Chabert et al. (2004) . When we used a 2-year cut-off to evaluate the patients' QoL over time, we found a tendency of patients to be more affected by their treatment in the first 2 years after the diagnosis. However, over the entire period from their diagnosis and treatment, UM patients had similar QoL scores in the items we measured. This indicates that time alone does not heal the psychological effects of this malignancy on the patients. Although most of these patients do well, the small subgroup that needs psychosocial help still needs it even years after the diagnosis and treatment. In conclusion, all patients need information about physical and psycho-social implications of treatment in the short and long term.
One can identify the patients who are in greater need for psychosocial intervention as those who are troubled by their eyes. This need arises immediately after the diagnosis and continues for years.
